SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors react to highly positive Phase 3 trial results for its hereditary angioedema therapy, marking a major milestone for in vivo CRISPR gene editing. While many in the community anticipate a potential short squeeze due to high short interest and the significant clinical success, others are warning of a 'sell-the-news' reaction following the stock's recent run-up.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is generating significant community excitement as investors anticipate critical clinical trial updates and a high-profile oral presentation at the upcoming Digestive Disease Week (DDW) conference. Supporters are highlighting the company's strong institutional backing and technical progress as key drivers, viewing the current market positioning as a strategic accumulation opportunity ahead of potential upcoming data catalysts.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is trending following a trading halt prompted by the news that its drug tovecimig did not meet the overall survival secondary endpoint in a Phase 2/3 study. The community is actively debating the implications for the company's regulatory path and future BLA filing, with significant skepticism regarding the trial design and statistical outcomes.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the Consumer and Business segments. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon is trending as investors respond to a multi-billion dollar share buyback program and strong subscriber growth fueled by competitive service pricing, which many in the community view as a successful defensive strategy against rivals. Market participants are actively discussing the stock's stability and consistent dividends as a pivot point for defensive positioning while tracking its recent breakout to multi-year highs.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is trending after a series of positive analyst initiations, including a new Buy rating with a 29 target, alongside excitement for its denifanstat program in both MASH and acne. Investors are actively discussing the stock's potential as a buyout candidate, comparing it to recent industry acquisitions, and are closely monitoring institutional accumulation patterns.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is capturing community attention as traders debate the coin's potential during the annual 'Doge Day' festivities, with sentiment split between long-term holders anticipating a breakout and skeptics focusing on consolidation patterns. The active discussion is driven by retail interest in meme coin volatility and ongoing speculation regarding future adoption or social media catalysts.

RE/MAX Holdings, Inc. engages in the provision of real estate franchise services through its subsidiaries. It operates through the following segments: Real Estate, Mortgage and Marketing Funds. The Real Estate segment consists of the company’s owned and independent global franchising operations under the RE/MAX brand name and technology and data subscription for Gadberry and the First app. The Mortgage segment consists of the firm's mortgage brokerage franchising operations under the Motto Mortgage brand name and mortgage loan processing services and licensed software under the wemlo brand. The Marketing Funds segment is involved in marketing campaigns designed to build and maintain brand awareness and the development and operation of agent marketing technology. The company was founded by David L. Liniger and Gail A. Liniger in 1973 and is headquartered in Denver, CO.

RE/MAX Holdings Inc - Ordinary Shares - Class A

RE/MAX Holdings is currently at the center of market discussions as investors weigh its potential for an acquisition against broader real estate sector challenges. While some in the community are optimistic about a potential takeout and the company's long-term brand value, others remain cautious due to the competitive landscape and ongoing industry consolidation.

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics Inc.

Oruka Therapeutics is experiencing significant market attention following positive Phase 2a results for its lead candidate ORKA-001 in treating moderate-to-severe plaque psoriasis. Investors are actively discussing the potential for clinical differentiation against established market leaders, while also debating the long-term impact of recent capital-raising activities and the company's ambitious valuation.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining momentum as a community-driven project fueled by active developer engagement, including consistent token airdrops and transparency regarding project milestones. Investors are closely tracking the token's ability to hold its floor following recent highs, with many in the community optimistic about its potential as a multi-day runner while they await upcoming chart integrations.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is attracting significant investor attention following reports that it is collaborating with OpenAI to develop AI-powered smartphone processors, a development seen as a major catalyst for the semiconductor sector. The community is actively discussing the stock's potential as an undervalued AI-at-the-edge play, with many traders debating the long-term impact of this partnership on mobile device innovation versus lingering concerns about handset market headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is First Trust NASDAQ Semiconductor ETF (FTXL) a Strong ETF Right Now?

<ul class="summary-bullets"><li>The memory chip-maker’s revenue nearly tripled to $23.86 billion from $8.05 billion in the same period of 2025.&nbsp;</li><li>Mehrotra said Micron’s record results were attributable to an increase in memory demand, driven by AI and structural supply constraints.</li><li>Retail users on Stocktwits flagged that the strong earnings results were expected, and also voiced concerns over the company’s high capital expenditure.</li></ul>Shares of Micron Technology Inc. (MU) fell more than 2.5% in Wednesday’s post-market session despite the company’s second-quarter (Q2) 2025 earnings results that blew past Wall Street expectations.The memory chip-maker’s revenue nearly tripled to $23.86 billion from $8.05 billion in the same period of the previous fiscal year. Meanwhile, analysts had forecast a revenue of $19.18 billion, according to Fiscal.ai. Earnings also beat consensus estimates, coming in at $12.20 per diluted share, compared to a Street projection of $8.66 per share.However, retail users on Stocktwits flagged that the strong earnings results were expected, while also voicing concerns over the company’s high capital expenditure.<h2 class="st-heading-2">Capital Expenditure</h2>Micron posted capital expenditures of $5 billion for the quarter, an increase of about 62% from the same period last year. For the upcoming quarter, the company projected capex of about $7 billion, and said full-year 2026 capital spending would be above $25 billion.President and CEO Sanjay Mehrotra said in a call with investors that the higher capex comes as the company builds out its global manufacturing sites to address long-term demand. Micron also expects higher equipment expenditures in fiscal 2027, he said.<h2 class="st-heading-2">Memory Supply Tightness</h2>Mehrotra said Micron’s record results were attributable to an increase in memory demand, driven by AI and structural supply constraints.He added that while additional server demand was robust, driven by a combination of demand from Agentic AI and broad-based servers, both segments were constrained by lack of adequate Dram and Nand supply. &nbsp;“Memory makes AI smarter and more capable, enabling longer context windows, deeper reasoning chains, and multi-agent orchestration, as AI evolves. We expect compute architectures to become more memory intensive. This is why we strongly believe that Micron is one of the biggest beneficiaries, and enablers of AI,” Mehrotra said.<h2 class="st-heading-2">Q3 Outlook</h2>For the third-quarter (Q3) of 2026, Micron forecast revenue of about $33.5 billion, plus or minus $750 million. Analysts projected revenue of $22.48 billion, according to Fiscal.ai. The company expects to record earnings per share of $19.15, plus or minus $0.40.<h2 class="st-heading-2">Street Action</h2>Following the earnings results, Summit Insights downgraded Micron to ‘Hold’ from ‘Buy,’ saying that the firm expects MU stock’s outperformance in the second half of FY26 to moderate, as per TheFly.Summit Insights added that while it sees favorable memory demand-supply dynamics and pricing through the first half of 2026, the firm also believes that price increases will likely decelerate meaningfully in FY26.Prior to the results, Bernstein analyst Mark Li raised the firm's price target on Micron to $510 from $330 and kept an ‘Outperform’ rating on the shares, saying global memory price increases are more than expected in Q2.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MU">MU shares</a> dropped from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours amid ‘high’ message volumes.One bullish user said that the strong earnings results were already baked into the share price.<stembedurl>https://stocktwits.com/stephanie666/message/647902900</stembedurl>&nbsp;However, another bearish user flagged the high capex, warning that demand would crater amid slowing data center growth.<stembedurl>https://stocktwits.com/azstockguy/message/647909992</stembedurl>&nbsp;Shares of the company have rallied more than 353% in the past year.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-gxai-stock-surge-today/cZ37F6PRIW7">Why Did GXAI Stock Surge More Than 13% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone held in a hand shows the logo of Micron Technology Inc. 

Micron Stock Falls Despite Blowout Q2 Results — Retail Sentiment Dips On Earnings Predictability, Capex Concerns

Micron Technology posted capital expenditures of $5 billion for the quarter, an increase of about 62% from the same period last year. 

Equity

Should You Invest in the First Trust NASDAQ Semiconductor ETF (FTXL)?

ETFs to Gain as Japan Pledges to Invest $36B in U.S. Projects

Japan's $36B U.S. investment targets energy, exports and minerals. ETFs like XLE could ride the industrial boost from this landmark pledge.

<ul class="summary-bullets"><li>Wells Fargo analyst Aaron Rakers cut his price target to $135 from $165 and emphasized ongoing memory supply concerns that are pressuring handset guidance.</li><li>Susquehanna analyst Christopher Rolland downgraded the stock to ‘Neutral’ from ‘Positive’, sharply lowering his price target to $140 from $210.</li><li>Bank of America pointed to continued weakness in the handset sector, noting that demand pressures appear both cyclical and structural.</li></ul>Qualcomm Inc. (QCOM) stock saw a slew of price target and rating changes from Wall Street as the chipmaker&nbsp;navigates headwinds in the memory market.For the second quarter (Q2), Qualcomm expects adjusted earnings per share (EPS) in the range of $2.45 to $2.65, and revenue between $10.2 billion and $11.0 billion, both below the analysts’ consensus estimate of $2.87 and $11.02&nbsp;billion, respectively, according to Fiscal AI data.&nbsp;<blockquote>“In the coming quarters, the handset industry will be constrained by the availability and pricing of memory, particularly DRAM.”-Cristiano Amon, President and CEO, Qualcomm</blockquote><h2 class="st-heading-2">Market Sentiment Shifts After Earnings And Headset Pressures</h2>JPMorgan analyst Samik Chatterjee trimmed the 12-month price target for Qualcomm to $185 from $195 while retaining an ‘Overweight’ rating on the stock, according to TheFly.&nbsp;&nbsp;The firm noted that management pointed to challenges in the wider smartphone industry as memory producers shift capacity toward high-bandwidth memory, tightening DRAM availability.Meanwhile, Wells Fargo analyst Aaron Rakers cut his price target to $135 from $165 and kept an ‘Underweight’ rating. The firm emphasized ongoing memory supply concerns that are pressuring handset guidance, as well as potential reductions in modem content with Apple’s iPhone lineup, a key driver of Qualcomm’s revenue.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://qualcomm">Qualcomm stock</a> traded over 7% lower by Thursday mid-morning. However, on Stocktwits, retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_05_113000_png_73ca6c5d60.webp" alt="QCOM’s Sentiment Meter and Message Volume as of 11:00 a.m. ET on Feb. 5, 2026 | Source: Stocktwits" width="924" height="105"><figcaption>QCOM’s Sentiment Meter and Message Volume as of 11:00 a.m. ET on Feb. 5, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Susquehanna And Bank of America Downgrade Qualcomm</h2>Susquehanna analyst Christopher Rolland downgraded the stock to ‘Neutral’ from ‘Positive’, sharply lowering his price target to $140 from $210. Rolland said the firm is choosing to remain on the sidelines as Qualcomm navigates what he described as a “memory-related handset storm.”&nbsp;Bank of America downgraded Qualcomm to ‘Neutral’ from ‘Buy’ and slashed its price target to $155 from $215. The firm pointed to continued weakness in the handset sector, noting that demand pressures appear both cyclical and structural.QCOM stock has declined 20% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ross-gerber-warns-of-intense-hardware-battle-as-ai-spending-sparks-competition-among-tech-leaders/cZbZaDhR4Vr">Ross Gerber Warns Of Intense Hardware Battle As AI Spending Sparks Competition Among Tech Leaders</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The microchip maker Qualcomm company logo.  (Photo by Davide Bonaldo/SOPA Images/LightRocket via Getty Images)

Qualcomm Slides as Weak Q2 Outlook And Memory Market Headwinds Trigger Analyst Downgrades, Price Target Revisions

JPMorgan analyst Samik Chatterjee trimmed the 12-month price target for Qualcomm to $185 from $195 while retaining an ‘Overweight’ rating, citing challenges in the wider smartphone industry amid tightening DRAM availability. 

Tap the Super-Hot Memory Market With These ETFs

Micron stands to benefit as AI demand drives a memory chip crunch through 2027, pushing prices higher and steering investors toward targeted ETFs.

ETFs to Buy as Intel Plunges 17% Despite Q4 Earnings Beat 

INTC shares plummet 17% after Q4 earnings release as weak Q1 guidance rattled investors, pushing Intel-heavy ETFs into focus for diversified exposure.  

<ul class="summary-bullets"><li>Northland Securities noted the company’s strategic importance to the U.S. and called the guidance “very likely to be conservative.”</li><li>Stifel described Intel’s Q4 results as a “robust beat,” but emphasized that Q1 projections reflect temporary inventory shortages.</li><li>Bank of America suggested that&nbsp; Intel’s current stock price exceeds its near-term ability to execute a profitable business model.&nbsp;</li></ul>Intel Corp. (INTC) stock continued to be in the spotlight on Friday after multiple analysts adjusted their price targets following the company’s fourth-quarter (Q4) earnings and cautious guidance for the first quarter (Q1) of 2026.&nbsp;Despite reporting stronger-than-expected earnings per share in Q4, Intel’s forecast for Q1 fell short of analysts’ predictions. The company expects revenue between $11.7 billion and $12.7 billion, with the lower end notably below the $12.5 billion analysts’ consensus estimate, according to Fiscal.ai.&nbsp;<h2 class="st-heading-2">Street Opinion</h2>Northland Securities raised its price target on Intel to $54 from $46 while maintaining an ‘Outperform’ rating, noting the company’s strategic importance to the U.S. and calling the guidance “very likely to be conservative,” according to TheFly.&nbsp;Meanwhile, UBS raised its target to $52 from $49, with a ‘Neutral’ rating, citing supply bottlenecks and structural limitations that may constrain Intel’s AI growth potential.&nbsp;<a href="https://stocktwits.com/symbol/INTC">Intel stock</a> traded 16% lower on Friday morning and was the top-trending equity ticker on Stocktwits. Retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_23_093030_png_56b886397e.webp" alt="INTC’s Sentiment Meter and Message Volume as of 09:45 a.m. ET on Jan. 23, 2026 | Source: Stocktwits" width="928" height="104"><figcaption>INTC’s Sentiment Meter and Message Volume as of 09:45 a.m. ET on Jan. 23, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Stifel Sees Long-Term Prospects Improving&nbsp;</h2>Stifel also adjusted its forecast, increasing the target to $42 from $35 while keeping a ‘Hold’ rating. The firm described Intel’s Q4 results as a “robust beat,” but emphasized that Q1 projections reflect temporary inventory shortages and high demand for server CPUs. Stifel expects Q1 to represent a fundamental low point, with longer-term prospects improving as production scales up.Meanwhile, Bank of America reaffirmed an ‘Underperform’ rating with a $40 price target, suggesting Intel’s current stock price exceeds its near-term ability to execute a profitable business model.&nbsp;In the Q4 earnings call, Intel CEO Lip-Bu Tan told that the rapid growth and broader adoption of AI tasks are putting heavy pressure on both existing and new hardware systems, highlighting how important CPUs have become in supporting AI technology.According to a CNBC&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/01/23/intel-stock-earnings-q4-2025-supply.html">report</a>, Jefferies said that though it recognizes the recent optimism around Intel’s potential, the firm still doesn’t see a clear direction ahead as the company lacks a defined AI plan, and faces uncertainty around its manufacturing and packaging business.INTC stock has gained over 117% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/super-micro-stock-gains-momentum-as-q2-earnings-date-sparks-investor-interest/cmyR4ABR4gg">Super Micro Stock Gains Momentum As Q2 Earnings Date Sparks Investor Interest</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Intel Corporation logo is being displayed on a smart phone, with an Intel chip visible in the background.

Intel Draws Mixed Street Reaction After Strong Q4 But Cautious 2026 Outlook 

UBS raised its target to $52 from $49, with a ‘Neutral’ rating, citing supply bottlenecks and structural limitations that may constrain Intel’s AI growth potential. 

<ul class="summary-bullets"><li>The company’s earnings per share also beat estimates, coming in at $0.15 versus street estimates of $0.08.</li><li>Intel projected a revenue of $11.7 billion to $12.7 billion for the next quarter, while street expectations were at $12.5 billion, as per Fiscal.ai data.</li><li>The company attributed the lower guidance to chip supply constraints, expected to be at its lowest level in Q1.</li></ul>Shares of Intel Corp. (INTC) slid over 12% in Thursday’s after-market hours as the company provided a soft outlook for the first-quarter (Q1) 2026 in its latest earnings update.Intel’s fourth-quarter (Q4) results, however, beat analyst expectations, reporting higher-than-expected revenue and earnings per share.<h2 class="st-heading-2">Results Snapshot</h2>Intel reported Q4 revenue of $13.7 billion, down 4% year-on-year, but beating analyst expectations of $13.3 billion, as per data from Fiscal.ai. The company’s earnings per share also beat estimates, coming in at $0.15 versus street estimates of $0.08.Meanwhile, the company’s full-year revenue for 2025 came in at $52.9 billion, beating street consensus of $52.5 billion.“We delivered a solid finish to the year and made progress on our journey to build a new Intel. The introduction of our first products on Intel 18A – the most advanced process technology developed and manufactured in the United States – marks an important milestone, and we’re working aggressively to grow supply to meet strong customer demand,” said Lip-Bu Tan, Intel’s CEO.However, the company’s outlook for Q1 2026 came in below street expectations. Intel projected a revenue of $11.7 billion to $12.7 billion, with the lower-end of the projection coming in much below street expectations of $12.5 billion, as per Fiscal.ai data.The chipmaker also projected earnings per share to be nil in the upcoming quarter, versus a street expectation of $0.05.<h2 class="st-heading-2">Supply Constraints</h2>The company attributed the lower guidance to chip supply constraints, expected to be at its lowest level in Q1. “As we enter 2026, our buffer inventory is depleted and the mix shift in wafers towards servers, which began in Q3, will not come out of fab until late Q1 26,” said Dave Zinsner, Intel’s Chief Financial Officer, during the earnings call.“As a result, and as we stated last quarter, our internal supply constraints are most acute in Q1,” he said. Zinsner added that while this is expected to improve in the following quarter, the company still “won’t be completely out of the woods here.”However, he said that things would improve through the year progressively. “We expect our factory network to improve available supply beginning in Q2, and for each of the remaining quarters in 2026,” Zinsner said.To manage limited capacity, Zinsner said Intel will be shifting its wafer supply away from lower-end PC products to prioritize mid- to high-end client chips. Any additional capacity would be redirected to data center products, where demand and strategic importance are higher.As a result, Intel expects some market-share fluctuations, but its priority is ensuring reliable supply to its largest and most important customers across both data center and client segments, Zinsner added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/INTC">INTC shares</a> remained in the ‘extremely bullish’ territory over the past day amid ‘extremely high’ message volumes.One user predicted the company’s shares would tank to $37 next week from the current $47 levels.<stembedurl>https://stocktwits.com/ProKnifeCatcher87/message/642621328</stembedurl>&nbsp;Another bearish user wondered about how the guidance could be lower, given the recent surge in AI, while touting ‘bubble popping’.https://stocktwits.com/azstockguy/message/642615489A bullish user, however, said the earnings were not so bad, highlighting the slew of products that Intel has lined up that would propel it forward in the long run.<stembedurl>https://stocktwits.com/Torjaner/message/642617742</stembedurl>&nbsp;Shares of INTC gained over 148% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Intel Shares Tank On Lackluster Q1 Outlook Despite Earnings Beat

Intel reported fourth-quarter revenue of $13.7 billion, beating analyst expectations of $13.3 billion, as per data from Fiscal.ai. 

Current Price	$210.00
Prev Close	$199.32
Open	$208.64
Dividend Yield	N/A
50-Day Moving Average	$161.06
Beta	N/A
Avg. Volume	146,023.29
PE Ratio	N/A

52-Week High	$210.60
52-Week Low	$71.34
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

FTXL
First Trust Exchange-Traded Fund III - First Trust Nasdaq Semiconductor ETF

Feed

News

Sentiment

Fundamentals

Info

Latest FTXL News

FTXLFirst Trust Exchange-Traded Fund III - First Trust Nasdaq Semiconductor ETF